Reacts with the 46 kDa protein corresponding to cytokeratin 20. The antibody is a useful aid for classification of adenocarcinomas of the colon, mucinous ovarian tumors, transitional-cell and Merkel-cell carcinomas, adenocarcinomas of the stomach, bile system and pancreas. Results also aid in the classification of most squamous cell carcinomas and most adenocarcinomas from other sites (breast, endometrium, lung, prostate), non-mucinous tumors of the ovary, and small-cell lung carcinomas as these may be negative.
This product is not available for purchase by the general public.
Optimized staining performance of both high and low-expression structures
Dako Omnis and the dynamic gap staining technology provides a consistent, uniform staining with excellent morphology
Crisp and clear staining with no background
Optimal laboratory efficiency with ready-to-use antibodies on Dako Omnis
The staining performance of all FLEX RTU antibodies has been defined, tested and approved through collaboration with leading, international pathology experts.
CK20 isolated by SDS-PAGE from cytoskeletal material obtained from human duodenal mucosa (1). See package insert for reference(s).
Ready-to-use monoclonal mouse antibody provided in liquid form in a buffer containing stabilizing protein and 0.015 mol/L sodium azide.
In Western immunoblotting of SDS-PAGE-separated cytoskeletal proteins from human duodenal mucosa, the antibody labels a 46 kDa polypeptide corresponding to CK20 (1). See package insert for reference(s).
1. Moll R, Löwe A, Laufer J, Franke WW. Cytokeratin 20 in human carcinomas. Am J Pathol 1992,140:427-47. 2. Harnden P, Mahmood N, Southgate J. Expression of cytokeratin 20 redefines urothelial papillomas of the bladder. Lancet 1999,353:974-7. 3. Chu P, Wu W, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol 2000,13:962-72.